Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NTRA

Natera Inc

Mar 06 • 04:00PM ET

198.13

+0.99 0.50 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH TXG EXAS QGEN FLGT TWST MYGN CDNA BNGO

| Held by: VTI VB VBK VXF IBB IWP IWF IWR VHT XBI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.54	Insider Own	4.86%	Shs Outstand	139.69M	Perf Week	-4.76%
Market Cap	28.08B	Forward P/E	-	EPS next Y	-0.50	Insider Trans	-11.16%	Shs Float	134.84M	Perf Month	-3.64%
Enterprise Value	27.22B	PEG	-	EPS next Q	-0.54	Inst Own	92.48%	Short Float	2.43%	Perf Quarter	-16.83%
Income	-208.16M	P/S	12.18	EPS this Y	-19.10%	Inst Trans	0.63%	Short Ratio	2.82	Perf Half Y	18.95%
Sales	2.31B	P/B	16.16	EPS next Y	72.34%	ROA	-9.93%	Short Interest	3.28M	Perf YTD	-13.51%
Book/sh	12.26	P/C	26.09	EPS next 5Y	-	ROE	-14.32%	52W High	256.36 -22.71%	Perf Year	40.02%
Cash/sh	7.59	P/FCF	257.37	EPS past 3/5Y	35.09% 11.70%	ROIC	-11.37%	52W Low	125.38 58.02%	Perf 3Y	249.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	41.14% 42.61%	Gross Margin	64.67%	Volatility	4.81% 4.27%	Perf 5Y	92.38%
Dividend TTM	-	EV/Sales	11.80	EPS Y/Y TTM	-0.51%	Oper. Margin	-13.27%	ATR (14)	9.22	Perf 10Y	2123.68%
Dividend Ex-Date	-	Quick Ratio	3.24	Sales Y/Y TTM	35.90%	Profit Margin	-9.03%	RSI (14)	37.23	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	3.39	EPS Q/Q	182.67%	SMA20	-4.91%	Beta	1.71	Target Price	260.76
Payout	-	Debt/Eq	0.13	Sales Q/Q	39.79%	SMA50	-11.50%	Rel Volume	1.06	Prev Close	197.14
Employees	6140	LT Debt/Eq	0.07	Earnings	Feb 26 AMC	SMA200	4.69%	Avg Volume	1.16M	Price	198.13
IPO	Jul 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	170.30% 10.18%	Trades		Volume	1,225,908	Change	0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Citigroup	Buy	$300
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Oct-27-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$172
Sep-22-25	Resumed	Wells Fargo	Equal Weight	$175
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90

Show Previous Ratings

Mar-04-26 07:10AM	Signatera Oncology Test Drives Natera's (NTRA) Growth (Insider Monkey)
Mar-03-26 03:35PM	Natera (NTRA) Stock Trades Up, Here Is Why (StockStory)
Feb-27-26 12:40PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)
10:05AM	Signatera MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation (Business Wire)
08:30AM	Personalis, Inc. Q4 2025 Earnings Call Summary (Moby)
12:07AM	Loading…
12:07AM	Natera Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Natera Inc (NTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook ... (GuruFocus.com)
Feb-26-26 11:53PM	Natera, Inc. (NTRA) Announces Results From the SINERGY Trial (Insider Monkey)
06:45PM	Natera (NTRA) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:30PM	Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:58PM	Natera: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-24-26 10:28PM	Natera Earnings: What To Look For From NTRA (StockStory)
06:00AM	Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer (Business Wire)
Feb-23-26 09:15AM	Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
07:00PM	Loading…
Feb-18-26 07:00PM	Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission (MarketBeat)
08:10AM	Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates (Zacks)
Feb-17-26 04:01PM	Stanley Druckenmiller's Strategic Moves: A Closer Look at State Street Financial Select Sector ... (GuruFocus.com)
09:00AM	Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026 (Business Wire)
Feb-12-26 07:27AM	Surgery Partners (SGRY) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Feb-11-26 09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
Feb-10-26 07:40AM	CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-06-26 06:00AM	Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes (Business Wire)
Feb-03-26 05:15PM	InnovAge Holding Corp. (INNV) Q2 Earnings and Revenues Surpass Estimates (Zacks) -9.69%
10:29AM	Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test (Zacks)
Feb-02-26 06:00AM	Natera Submits Signatera CDx PMA to FDA (Business Wire)
Jan-29-26 07:29AM	Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue (Insider Monkey)
Jan-26-26 06:00AM	Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care (Business Wire)
Jan-25-26 11:38PM	2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds (StockStory)
Jan-23-26 10:53AM	Lack of Natera (NTRA) Exposure Weighs on Mid-Cap Fund Performance (Insider Monkey)
06:00AM	Loading…
Jan-21-26 06:00AM	Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer (Business Wire)
Jan-20-26 06:00AM	Natera's Fetal Focus Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting (Business Wire)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:00AM	Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling (Business Wire)
Jan-12-26 10:00AM	Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA (Business Wire)
Jan-11-26 10:48PM	Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth (Business Wire)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks) -5.83%
Jan-07-26 02:11PM	Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera (CNBC TV)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
08:04AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonalds, Moderna, and More (24/7 Wall St.)
08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire)
Jan-05-26 07:25PM	Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI (Business Wire)
07:00AM	Natera Launches 21-Gene Fetal Focus Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP Technology (Business Wire)
Dec-31-25 11:56AM	Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study (Insider Monkey)
Dec-30-25 02:16PM	Medical Stock Hovers Near Buy Point After 46% Gain (Investor's Business Daily)
Dec-26-25 03:40PM	Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens (Investor's Business Daily)
Dec-23-25 11:03PM	3 Reasons We're Fans of Natera (NTRA) (StockStory)
Dec-22-25 10:19PM	J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum (Insider Monkey)
08:00AM	Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-25 08:00AM	Natera Announces Publication of Signatera Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer (Business Wire)
Dec-12-25 08:00AM	Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer (Business Wire)
Dec-11-25 10:11AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
10:11AM	Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks (24/7 Wall St.)
Dec-10-25 07:57PM	Phase III PALLAS Study Shows Signatera MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer (Business Wire)
06:15AM	Natera acquires Foresight Diagnostics for up to $450M (MedTech Dive)
Dec-09-25 08:00AM	Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting (Business Wire)
Dec-08-25 04:46AM	Natera purchases Foresight Diagnostics (Medical Device Network)
Dec-05-25 07:00AM	Natera Acquires Foresight Diagnostics (Business Wire)
Dec-03-25 08:00AM	New Signatera Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting (Business Wire)
Dec-02-25 08:00AM	Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera at the San Antonio Breast Cancer Symposium (Business Wire)
Nov-30-25 03:14AM	30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks (Motley Fool)
Nov-24-25 07:00PM	Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know (StockStory)
12:38PM	This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks Hes Buying Now. (24/7 Wall St.)
Nov-21-25 06:55PM	Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know (StockStory)
Nov-20-25 01:25PM	Cathie Wood Targets New Tech Winners, Dumps AMD in Major Shuffle (GuruFocus.com)
Nov-19-25 10:40PM	Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3 (StockStory)
08:00AM	Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month (Business Wire)
Nov-18-25 04:45AM	TD Cowen Lifts Natera (NTRA) Target to $240, Reiterates Buy Rating (Insider Monkey)
Nov-14-25 03:05PM	Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ... (GuruFocus.com)
07:58AM	Does Natera (NTRA) Have a Long Runway For Growth? (Insider Monkey)
Nov-12-25 08:00AM	Natera Integrates with Flatiron Health's OncoEMR Platform (Business Wire)
Nov-11-25 11:39PM	1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds (StockStory)
Nov-07-25 09:27AM	NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase (StockStory)
12:03AM	Natera Inc (NTRA) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions (GuruFocus.com)
Nov-06-25 07:30PM	Here's What Key Metrics Tell Us About Natera (NTRA) Q3 Earnings (Zacks)
05:50PM	Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:02PM	Natera (NASDAQ:NTRA) Delivers Impressive Q3 (StockStory)
04:46PM	Natera: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-04-25 10:19PM	Natera (NTRA) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-31-25 07:00AM	Natera Announces Expansion to 20 Genes for its Fetal Focus Single-Gene NIPT (Business Wire)
Oct-30-25 07:00AM	Natera to Report its Third Quarter Results on November 6, 2025 (Business Wire)
Oct-28-25 07:00AM	Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity (Business Wire)
Oct-27-25 06:20AM	Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 11:31PM	Reflecting On Immuno-Oncology Stocks' Q2 Earnings: Natera (NASDAQ:NTRA) (StockStory)
01:35PM	Why Are Natera (NTRA) Shares Soaring Today (StockStory)
01:05AM	Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients (Business Wire)
Oct-16-25 08:00AM	Natera Named to Fast Company's Next Big Things in Tech List (Business Wire)
Oct-13-25 09:28AM	Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer (Insider Monkey)
08:00AM	Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings (Business Wire)
Oct-12-25 06:10PM	Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium (Business Wire)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Sep-30-25 08:00AM	Natera Announces Publication of Signatera Validation Study in Testicular Cancer (Business Wire)
Sep-29-25 08:00AM	Signatera Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows (Business Wire)
12:36AM	2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds (StockStory)
Sep-24-25 04:05PM	Why Natera (NTRA) Stock Is Down Today (StockStory) -5.16%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-22-25 09:35AM	Humana initiated, Paycom upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 04:01PM	Why Natera (NTRA) Stock Is Trading Lower Today (StockStory)
Sep-10-25 03:11PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DANIEL RABINOWITZ	Officer	Mar 06 '26	Proposed Sale	197.14	16,798	3,311,558		Mar 06 04:29 PM
Sheena Jonathan	CO-FOUNDER	Mar 02 '26	Sale	200.23	3,070	614,710	262,194	Mar 03 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 02 '26	Sale	200.02	3,950	790,095	156,607	Mar 03 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 02 '26	Option Exercise	9.59	5,125	49,149	153,023	Mar 03 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 02 '26	Sale	199.85	3,000	599,545	150,023	Mar 03 09:05 PM
STEVEN L CHAPMAN	Officer	Mar 02 '26	Proposed Sale	200.02	3,950	790,095		Mar 02 04:12 PM
SOLOMON MOSHKEVICH	Officer	Mar 02 '26	Proposed Sale	199.85	3,000	599,545		Mar 02 04:11 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 02 '26	Sale	231.44	3,000	694,309	139,486	Feb 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 03 '26	Sale	230.77	1,639	378,229	137,847	Feb 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 02 '26	Sale	230.72	85,299	19,680,040	127,881	Feb 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 03 '26	Sale	230.77	4,725	1,090,379	123,156	Feb 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 03 '26	Sale	227.83	6,939	1,580,926	52,120	Feb 04 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Feb 03 '26	Sale	231.02	3,594	830,279	178,081	Feb 04 09:05 PM
Sheena Jonathan	CO-FOUNDER	Feb 03 '26	Sale	230.77	435	100,384	263,161	Feb 04 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 03 '26	Sale	230.77	1,334	307,845	223,813	Feb 04 09:05 PM
MICHAEL BROPHY	Officer	Feb 03 '26	Proposed Sale	231.10	5,671	1,310,568		Feb 03 04:32 PM
STEVEN L CHAPMAN	Officer	Feb 02 '26	Proposed Sale	230.72	85,299	19,679,799		Feb 02 04:58 PM
SOLOMON MOSHKEVICH	Officer	Feb 02 '26	Proposed Sale	231.44	3,000	694,309		Feb 02 04:12 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 28 '26	Sale	237.66	3,648	866,992	213,180	Jan 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 27 '26	Sale	240.53	2,322	558,514	216,828	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 28 '26	Sale	237.56	2,413	573,221	60,926	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 29 '26	Sale	230.40	1,867	430,156	59,059	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 27 '26	Sale	240.53	784	188,577	63,339	Jan 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 27 '26	Sale	240.53	291	69,995	263,787	Jan 29 08:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 28 '26	Sale	237.66	191	45,394	263,596	Jan 29 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 28 '26	Sale	237.66	1,000	237,662	225,147	Jan 29 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 27 '26	Sale	240.53	886	213,111	226,147	Jan 29 08:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 28 '26	Sale	237.66	1,200	285,195	142,486	Jan 29 08:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 27 '26	Sale	240.53	1,013	243,658	143,686	Jan 29 08:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 28 '26	Sale	237.66	928	220,551	175,540	Jan 29 08:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 27 '26	Sale	240.53	784	188,577	176,468	Jan 29 08:35 PM
MICHAEL BROPHY	Officer	Jan 29 '26	Proposed Sale	235.93	1,867	440,481		Jan 29 04:10 PM
MICHAEL BROPHY	Officer	Jan 28 '26	Proposed Sale	240.34	1,176	282,640		Jan 28 04:19 PM
Sheena Jonathan	CO-FOUNDER	Jan 23 '26	Sale	243.94	1,500	365,914	21,782	Jan 27 08:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 20 '26	Sale	234.74	71,932	16,885,203	217,354	Jan 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 21 '26	Sale	235.00	1,590	373,650	219,150	Jan 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 21 '26	Sale	242.54	37,175	9,016,585	64,123	Jan 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 20 '26	Sale	234.74	23,948	5,621,515	99,776	Jan 22 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 21 '26	Sale	234.46	3,163	741,612	264,078	Jan 22 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jan 20 '26	Sale	234.74	2,981	699,755	267,050	Jan 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 20 '26	Sale	234.74	19,234	4,514,958	226,615	Jan 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 21 '26	Sale	235.00	438	102,930	227,033	Jan 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 20 '26	Sale	234.74	23,205	5,447,105	144,992	Jan 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 21 '26	Sale	235.00	293	68,855	144,699	Jan 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 20 '26	Sale	234.74	17,806	4,179,752	177,591	Jan 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 21 '26	Sale	235.00	339	79,665	177,252	Jan 22 09:05 PM
MICHAEL BROPHY	Officer	Jan 21 '26	Proposed Sale	234.85	36,573	8,589,169		Jan 21 04:54 PM
Sheena Jonathan	CO-FOUNDER	Jan 05 '26	Option Exercise	9.59	39,615	379,908	262,581	Jan 06 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 02 '26	Sale	228.95	2,951	675,621	123,499	Jan 06 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 02 '26	Sale	229.08	3,848	881,482	136,568	Jan 06 09:05 PM
SOLOMON MOSHKEVICH	Officer	Jan 02 '26	Proposed Sale	228.95	2,951	675,621		Jan 02 04:13 PM
STEVEN L CHAPMAN	Officer	Jan 02 '26	Proposed Sale	229.08	3,848	881,482		Jan 02 04:13 PM
Sheena Jonathan	CO-FOUNDER	Dec 19 '25	Sale	225.94	1,500	338,914	22,532	Dec 22 08:05 PM
Sheena Jonathan	Director	Dec 19 '25	Proposed Sale	220.00	4,500	990,000		Dec 19 10:03 AM
Sheena Jonathan	CO-FOUNDER	Dec 17 '25	Sale	227.01	3,070	696,912	222,966	Dec 17 08:35 PM
Sheena Jonathan	Director	Dec 17 '25	Proposed Sale	228.00	9,210	2,099,880		Dec 17 11:44 AM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 12 '25	Option Exercise	9.59	22,376	214,586	126,565	Dec 16 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 12 '25	Sale	230.76	4,692	1,082,714	113,065	Dec 16 09:05 PM
ROSENMAN HERM	Director	Dec 12 '25	Sale	227.42	48,419	11,011,477	20,342	Dec 16 09:05 PM
SOLOMON MOSHKEVICH	Officer	Dec 12 '25	Proposed Sale	230.76	4,692	1,082,714		Dec 12 05:17 PM
Herm Rosenman Trust	Board member	Dec 12 '25	Proposed Sale	233.13	48,419	11,287,921		Dec 12 10:07 AM
Sheena Jonathan	CO-FOUNDER	Dec 09 '25	Option Exercise	9.29	4,436	41,210	227,096	Dec 11 08:35 PM
Chapman Rowan E	Director	Dec 05 '25	Option Exercise	32.15	4,000	128,600	10,143	Dec 09 08:35 PM
Chapman Rowan E	Director	Dec 05 '25	Sale	243.10	4,366	1,061,389	5,777	Dec 09 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Dec 04 '25	Option Exercise	19.68	6,902	135,831	208,601	Dec 08 09:55 PM
ROWAN EMMA CHAPMAN	Director	Dec 05 '25	Proposed Sale	243.10	4,366	1,061,391		Dec 05 07:25 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 01 '25	Sale	238.15	3,000	714,459	109,061	Dec 03 08:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Dec 01 '25	Sale	238.07	4,400	1,047,502	140,416	Dec 03 08:35 PM
STEVEN L CHAPMAN	Officer	Dec 01 '25	Proposed Sale	238.07	4,400	1,047,501		Dec 01 04:10 PM
SOLOMON MOSHKEVICH	Officer	Dec 01 '25	Proposed Sale	238.15	3,000	714,459		Dec 01 04:08 PM
BOTHA ROELOF	Director	Nov 24 '25	Sale	236.12	75,000	17,708,936	1,154,198	Nov 26 05:00 PM
BV369 TRUST	Affiliate	Nov 24 '25	Proposed Sale	236.12	75,000	17,709,000		Nov 24 04:50 PM
Sheena Jonathan	CO-FOUNDER	Nov 20 '25	Sale	225.08	10,000	2,250,816	222,660	Nov 21 08:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 21 '25	Sale	230.01	4,000	920,030	23,282	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Option Exercise	41.17	7,668	315,689	26,027	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Option Exercise	40.93	5,112	209,234	23,471	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Sale	223.08	7,668	1,710,600	18,359	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Sale	215.00	5,112	1,099,088	18,359	Nov 21 08:05 PM
ROY BAYNES	Director	Nov 20 '25	Proposed Sale	223.08	7,668	1,710,600		Nov 20 04:03 PM
Sheena Jonathan	Director	Nov 20 '25	Proposed Sale	225.02	10,000	2,250,186		Nov 20 11:21 AM
ROY BAYNES	Director	Nov 19 '25	Proposed Sale	215.00	5,112	1,099,088		Nov 19 04:04 PM
Sheena Jonathan	CO-FOUNDER	Nov 07 '25	Sale	192.56	3,070	591,159	232,660	Nov 12 08:35 PM
Sheena Jonathan	CO-FOUNDER	Nov 11 '25	Sale	207.96	1,500	311,934	25,282	Nov 12 08:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 04 '25	Sale	200.51	22,900	4,591,674	2,280,852	Nov 04 09:35 PM
Sheena Jonathan	CO-FOUNDER	Nov 03 '25	Sale	200.07	4,000	800,274	26,032	Nov 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Nov 03 '25	Sale	198.60	3,000	595,810	112,061	Nov 04 09:35 PM
Marcus Gail Boxer	Director	Nov 03 '25	Sale	198.71	122	24,243	5,762	Nov 04 09:05 PM
MATTHEW RABINOWITZ	Director	Nov 04 '25	Proposed Sale	198.23	22,900	4,539,467		Nov 04 04:33 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 03 '25	Option Exercise	116.02	155,679	18,062,483	305,519	Nov 03 09:40 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 03 '25	Sale	199.96	160,703	32,133,981	144,816	Nov 03 09:40 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 03 '25	Sale	200.00	17,100	3,420,003	2,303,752	Nov 03 09:35 PM
MATTHEW RABINOWITZ	Director	Nov 03 '25	Proposed Sale	198.93	17,100	3,401,703		Nov 03 04:26 PM
SOLOMON MOSHKEVICH	Officer	Nov 03 '25	Proposed Sale	198.60	3,000	595,810		Nov 03 04:07 PM
STEVEN L CHAPMAN	Officer	Nov 03 '25	Proposed Sale	199.96	160,703	32,133,983		Nov 03 04:03 PM
Gail Marcus	Director	Nov 03 '25	Proposed Sale	198.71	122	24,243		Nov 03 01:24 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 28 '25	Sale	191.46	3,680	704,580	149,840	Oct 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 27 '25	Sale	192.32	2,335	449,077	153,520	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 28 '25	Sale	191.16	2,415	461,648	65,993	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 29 '25	Sale	190.64	1,867	355,925	64,126	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 27 '25	Sale	192.32	781	150,205	68,408	Oct 29 09:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTRA

Natera Inc

Upgrade your FINVIZ experience